Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study
BACKGROUND: Guideline-directed medical therapy is central to secondary prevention after acute coronary syndrome (ACS), but recommendations are usually framed at the medication-class level. In discharge practice, clinicians must select individual agents, especially in older patients with multivessel coronary disease. This study described discharge prescribing patterns and examined associations between within-class medication choices and short-term major adverse cardiovascular events (MACE). METHODS: This prospective, multicenter, real-world observational cohort included 277 patients aged ≥60 years with ACS and multivessel coronary disease. The primary outcome was 3-month MACE. Risk ratios (RRs) were estimated using modified Poisson regression with robust standard errors. RESULTS: Core secondary prevention therapies were frequently prescribed, including dual antiplatelet therapy in 99.3% and statins in 99.6%. In fully adjusted within-class analyses, ticagrelor versus clopidogrel had an RR of 0.70 for short-term MACE (95% CI, 0.40-1.21; P = 0.203), empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93-2.59; P = 0.094), and rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79-1.85; P = 0.372). Exploratory subgroup analyses showed nominal signals for ticagrelor versus clopidogrel among patients with frailty (RR, 0.36; 95% CI, 0.15-0.89; P = 0.026), and for empagliflozin versus dapagliflozin among patients with left ventricular ejection fraction <50% (RR, 1.86; 95% CI, 1.07-3.21; P = 0.027) and non-ST-segment elevation acute coronary syndrome (RR, 2.26; 95% CI, 1.05-4.88; P = 0.037). However, none remained statistically significant after adjustment for multiple comparisons. CONCLUSIONS: In older patients with ACS and multivessel disease, secondary prevention was widely implemented. Within-class comparisons showed no clear short-term MACE differences, while subgroup signals require validation.
Authors
- Thang Viet Luong (ORCID: https://orcid.org/0009-0008-5109-9115)
- Hung Minh Nguyen (ORCID: https://orcid.org/0009-0003-4278-8238)
- Phuc Thien Tran
- Binh Anh Ho
- Hai Nguyen Ngoc Dang (ORCID: https://orcid.org/0009-0006-4512-4658)
- Tan Van Nguyen
Institutions
- University of Tasmania (AU)
- Duy Tan University (VN)
- University of Medicine and Pharmacy at Ho Chi Minh City (VN)
- Hue Central Hospital (VN)
- Bạch Mai Hospital (VN)
- Thong Nhat Hospital (VN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1371/journal.pone.0355518
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00